BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: BMS-354825 may stop the growth of cancer cells by stopping the enzymes necessary
for cancer cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of BMS-354825 in
treating patients with chronic phase chronic myelogenous leukemia that is resistant to
imatinib mesylate.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)